Clementia Pharmaceuticals (CMTA) Hits New 1-Year High at $26.73

Clementia Pharmaceuticals Inc (NASDAQ:CMTA)’s share price reached a new 52-week high on Monday . The stock traded as high as $26.73 and last traded at $26.38, with a volume of 131024 shares trading hands. The stock had previously closed at $26.49.

Several research firms have weighed in on CMTA. Svb Leerink lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $26.00 target price on the stock. in a report on Tuesday, February 26th. Bloom Burton lowered shares of Clementia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 26th. Robert W. Baird lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Monday, March 4th. Wedbush lowered shares of Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Monday, February 25th. Finally, ValuEngine upgraded shares of Clementia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 25th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Clementia Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.00.

The firm has a market capitalization of $1.00 billion, a P/E ratio of -3.32 and a beta of 0.64.

Hedge funds have recently modified their holdings of the company. Northern Trust Corp lifted its holdings in shares of Clementia Pharmaceuticals by 16.8% in the 4th quarter. Northern Trust Corp now owns 16,211 shares of the company’s stock worth $191,000 after acquiring an additional 2,335 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Clementia Pharmaceuticals in the 4th quarter worth approximately $292,000. UBS Oconnor LLC acquired a new position in shares of Clementia Pharmaceuticals in the 4th quarter worth approximately $463,000. Geode Capital Management LLC lifted its holdings in shares of Clementia Pharmaceuticals by 90.6% in the 4th quarter. Geode Capital Management LLC now owns 40,638 shares of the company’s stock worth $477,000 after acquiring an additional 19,317 shares during the last quarter. Finally, Opaleye Management Inc. lifted its holdings in shares of Clementia Pharmaceuticals by 0.8% in the 4th quarter. Opaleye Management Inc. now owns 150,000 shares of the company’s stock worth $1,764,000 after acquiring an additional 1,168 shares during the last quarter. Hedge funds and other institutional investors own 78.72% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/clementia-pharmaceuticals-cmta-hits-new-1-year-high-at-26-73.html.

About Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.

Recommended Story: What is Depreciation?

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.